Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia

European Journal of Pharmacology

Volumn 454, Issue 2-3, 2002, Pages 145-151

  Richter, Angelika ^a   Löscher, Wolfgang ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Basal ganglia; Cannabinoid; Dystonia; Movement disorder

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CATALEPSY; CHOREOATHETOSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DYSKINESIA; DYSTONIA; FEMALE; HAMSTER; MALE; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRESS; ANIMAL; CHOREA; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; PHYSIOLOGY; SYRIAN HAMSTER;

ANIMALS; CANNABIDIOL; CANNABINOIDS; CHOREATIC DISORDERS; CRICETINAE; DISEASE MODELS, ANIMAL; DYSTONIA; ENDOCANNABINOIDS; FEMALE; MALE; MESOCRICETUS; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037111407     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02477-9     Document Type: Article

References (38)

1. sz mutants. J. Neurosci. 21(RC153):2001;1-4.
2. Cadogan A.-K., Alexander S.P.H., Boyd A.E., Kendall D.A. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. 69:1997;1131-1137.
3. Consroe P., Sandyk R., Snider S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30:1986;277-282.
4. Consroe P., Musty R., Conti L. Effects of cannabidiol in animal models of neurological dysfunctions. Chester G., Consroe P., Musty R. Marijuana: an International Research Report; Proceedings of the Melbourne Symposium on Cannabis. 1988;147-151 Australian Government Publishing Service, Canberra.
5. Demirkiran M., Jankovic J. Paroxysmal diskinesias: clinical features and classification. Ann. Neurol. 38:1995;571-579.
6. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. Fahn S. Medical treatment of dystonia. Tsui J.K.C., Calne D.B. Handbook of Dystonia. 1995;317-328 Marcel Dekker, New York.
8. Fahn S., Bressman S.B., Marsden C.D. Classification of dystonia. Fahn S., Marsden C.D., DeLong M.R. Dystonia 3. Advances in Neurology. vol. 78:1998;1-10 Lippincott-Raven, New York.
9. Fredow G., Löscher W. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur. J. Pharmacol. 192:1991;207-219.
10. Gerdemann G., Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85:2001;468-471.
11. Gernert M., Hamann M., Bennay M., Löscher W., Richter A. Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia. J. Neurosci. 20:2000;7052-7058.
12. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci. 2:1999;358-363.
13. Hashimoto T. Neuronal activity in the globus pallidus in primary dystonia and off-period dystonia. J. Neurol. 247:2000;49-52.
14. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991;267-274.
15. Huang C.C., Lo S.W., Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532.3:2001;731-748.
16. Kathmann M., Bauer U., Schlicker E., Göthert M. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;466-470.
17. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., Haycock D.A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1993;1352-1363.
18. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14:2001;1827-1832.
19. Löscher W., Fisher J.E. Jr., Schmidt D., Fredow G., Hönack D., Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov. Dis. 4:1989;219-232.
20. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
21. Miller A.S., Walker J.M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. 279:1995;179-185.
22. Miller A.S., Walker J.M. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur. J. Pharmacol. 352:1998;199-205.
23. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
24. Nobrega J.N., Richter A., Tozman N., Jiwa D., Löscher W. Quantitative autoradiography reveals regionally selective changes in dopamine D1 and D2 receptor binding in the genetically dystonic hamster. Neuroscience. 71:1996;927-936.
25. Pertwee R.G. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24:1993;811-824.
26. Rehders H.J., Löscher W., Richter A. Evidence for striatal overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience. 97:2000;267-277.
27. Richter A., Löscher W. (+)-WIN-55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur. J. Pharmacol. 264:1994;371-377.
28. Richter A., Löscher W. Pathophysiology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54:1998;633-677.
29. Richter A., Löscher W. Animal models of dystonia. Funct. Neurol. 15:2000;259-267.
30. Richter A., Raymond R., Barlow K., Hamann M., Nobrega J.N. Changes in AMPA receptor binding in a genetic model of paroxysmal dyskinesia. Naunyn-Schmiedeberg's Arch. Pharmacol. 365(Suppl. 1):2002;334.
31. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
32. Sandyk R., Snider S.R., Consroe P. Cannabidiol in dystonic movement disorders. Psychiatry Res. 18:1986;291.
33. Saňudo-Peňa M.C., Tsou K., Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65:1999;703-713.
34. Saňudo-Peňa M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur. J. Pharmacol. 391:2000;269-274.
35. Self D.W. Anandamide: a candidate neurotransmitter heads for the big leagues. Nat. Neurosci. 2:1999;303-304.
36. Showalter V.M., Conpton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
37. Szabo B., Dörner L., Pfreundtner C., Nörenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
38. Todd R.D., Perlmutter J.S. Mutational and biochemical analysis of dopamine in dystonia. Mol. Neurobiol. 16:1998;135-147.